

Resource Summary Report

Generated by [ASWG](#) on Aug 9, 2026

CD14 FITC MphiP9 ASR

RRID:AB_400086

Type: Antibody

Proper Citation

BD Biosciences Cat# 340682, RRID:AB_400086

Antibody Information

URL: http://antibodyregistry.org/AB_400086

Proper Citation: BD Biosciences Cat# 340682, RRID:AB_400086

Target Antigen: CD14

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD14 FITC MphiP9 ASR

Description: This monoclonal targets CD14

Target Organism: human

Clone ID: M??P9

Antibody ID: AB_400086

Vendor: BD Biosciences

Catalog Number: 340682

Record Creation Time: 20250820T021430+0000

Record Last Update: 20250820T130406+0000

Ratings and Alerts

No rating or validation information has been found for CD14 FITC MphiP9 ASR.

No alerts have been found for CD14 FITC MphiP9 ASR.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Bayes-Genis A, et al. (2024) Implantation of a double allogeneic human engineered tissue graft on damaged heart: insights from the PERISCOPE phase I clinical trial. EBioMedicine, 102, 105060.

Ott PA, et al. (2020) A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 183(2), 347.

Poran A, et al. (2020) Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. Cell reports. Medicine, 1(8), 100141.